426 results on '"Hus, Marek"'
Search Results
2. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
3. Analysis of Predictive Factors for Early Response to Ruxolitinib in 320 Patients with Myelofibrosis From the Polish Adult Leukemia Group (PALG) Registry
4. Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
5. Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM).
6. Predicting chemotherapy toxicity in multiple myeloma: the prognostic value of pre-treatment serum cytokine levels of interleukin-6, interleukin-8, monocyte chemoattractant protein-1, and vascular endothelial growth factor
7. Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria.
8. Stem Cell Mobilization Performed with Different Doses of Cytarabine in Plasma Cell Myeloma Patients Relapsing after Previous Autologous Hematopoietic Cell Transplantation—A Multicenter Report by the Polish Myeloma Study Group.
9. IL1B Polymorphism (rs1143634) and IL-1β Plasma Concentration as Predictors of Nutritional Disorders and Prognostic Factors in Multiple Myeloma Patients
10. Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).
11. Physiological and Molecular Responses of Pyrus pyraster Seedlings to Salt Treatment Analyzed by miRNA and Cytochrome P450 Gene-Based Markers
12. TREES AS A PART OF SMALL SACRAL ARCHITECTURE IN THE LIPTOV REGION
13. Predicting chemotherapy toxicity in multiple myeloma: the prognostic value of pretreatment serum cytokine levels of interleukin-6, interleukin-8, monocyte chemoattractant protein-1, and vascular endothelial growth factor.
14. Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors
15. The Clinical Relevance of Selected Cytokines in Newly Diagnosed Multiple Myeloma Patients
16. Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen
17. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
18. MM-533 Low-Dose Belantamab Mafodotin (Belamaf) in Combination With Nirogacestat Versus Belamaf Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 DREAMM-5 Platform Sub-Study 3
19. POSTER: MM-533 Low-Dose Belantamab Mafodotin (Belamaf) in Combination With Nirogacestat Versus Belamaf Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 DREAMM-5 Platform Sub-Study 3
20. Reading between the lines – complete blood count parameters as prognostic factors in patients with newly diagnosed acute myeloid leukemia
21. S183: PHASE III RANDOMIZED, MULTICENTER, OPEN-LABEL COMMODORE 1 TRIAL: COMPARISON OF CROVALIMAB VS ECULIZUMAB IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
22. P491: DAY 14 MEASURABLE RESIDUAL DISEASE ASSESSMENT PREDICTS TREATMENT OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY - RESULTS OF THE PALG-AML1/2016 STUDY
23. P913: LOW-DOSE BELANTAMAB MAFODOTIN (BELAMAF) IN COMBINATION WITH NIROGACESTAT VS BELAMAF MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1/2 DREAMM-5 PLATFORM SUB-STUDY 3
24. P864: A PHASE 1 STUDY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH STANDARD OF CARE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF DREAMM-9
25. Effect of Substrate Salinity on Growth of Juvenile Plants Pyrus pyraster (L.) Burgsd
26. Age-dependent determinants of infectious complications profile in children and adults after hematopoietic cell transplantation: lesson from the nationwide study
27. TLR2 Expression on Leukemic B Cells from Patients with Chronic Lymphocytic Leukemia
28. Analiza skuteczności ibrutynibu w podgrupie chorych na przewlekłą białaczkę limfocytową z delecją 17p: badanie obserwacyjne Polskiej Grupy ds. Leczenia Białaczek u Dorosłych (PALG)
29. A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9.
30. SARS-CoV-2 infection in patients with multiple myeloma: survey in 23 centers across Europe and USA
31. The TT Genotype of the KIAA1524 rs2278911 Polymorphism Is Associated with Poor Prognosis in Multiple Myeloma
32. Comparison of SOX2 and POU5F1 Gene Expression in Leukapheresis-Derived CD34+ Cells before and during Cell Culture
33. Haemophagocytic lymphohistiocytosis: case series. Serum ferritin level as an indicator of treatment effectiveness
34. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
35. Chronic active Epstein-Barr virus infection as the basis of neoplasm development. Transformation of chronic lymphocytic leukaemia to NK-cell lymphoma/leukaemia was observed by flow cytometry – a diagnostic report
36. Zmiany białaczkowe w ośrodkowym układzie nerwowym w przebiegu przewlekłej białaczki limfocytowej
37. RAPORT MEDYCZNEJ RACJI STANU: WYZWANIA ZDROWIA - POCZUCIE BEZPIECZEŃSTWA. PERSPEKTYWA 2022-2023. REPORT OF THE MEDICAL REASON OF STATE: HEALTH CHALLENGES - SENSE OF SECURITY. PERSPECTIVE 2022-2023
38. RAPORT: VII SPOTKANIE RADY EKSPERTÓW DS. CHORÓB RZADKICH MEDYCZNEJ RACJI STANU. REPORT: 7th MEETING OF THE COUNCIL OF EXPERTS FOR RARE DISEASES FOR A MEDICAL REASON
39. Thalidomide can promote erythropoiesis by induction of STAT5 and repression of external pathway of apoptosis resulting in increased expression of GATA-1 transcription factor
40. Optimizing the Treatment of Patients With Multiple Myeloma and Renal Impairment
41. Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)
42. A Comparison of Outcomes in Patients with Secondary Acute Promyelocytic Leukemia (APL) and De Novo APL - a Case-Match Retrospective Analysis of Polish Adult Leukemia Group (PALG)
43. Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study
44. A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)
45. Patient with orbital involvment by mycosis fungoides and COVID-19
46. Studies on platelet function during the first year of ibrutinib treatment in patients with chronic lymphocytic leukemia
47. Acute intermittent porphyria: a diagnostic challenge.
48. Expression of immune checkpoints on peripheral blood cells in patients with prostate cancer
49. MiRNA as a Potential Target for Multiple Myeloma Therapy–Current Knowledge and Perspectives
50. Level of depression and occurrence of cognitive changes in patients with multiple myeloma - a preliminary report
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.